CN118845957A - A hangover-relieving composition and preparation method thereof - Google Patents
A hangover-relieving composition and preparation method thereof Download PDFInfo
- Publication number
- CN118845957A CN118845957A CN202410941442.XA CN202410941442A CN118845957A CN 118845957 A CN118845957 A CN 118845957A CN 202410941442 A CN202410941442 A CN 202410941442A CN 118845957 A CN118845957 A CN 118845957A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- hangover
- stir
- relieving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 206010019133 Hangover Diseases 0.000 title claims description 32
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 11
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 11
- 241000234435 Lilium Species 0.000 claims abstract description 10
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 238000004140 cleaning Methods 0.000 claims abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 6
- 235000011477 liquorice Nutrition 0.000 claims abstract description 6
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 15
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 14
- 241000675108 Citrus tangerina Species 0.000 claims description 13
- 244000010000 Hovenia dulcis Species 0.000 claims description 12
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 12
- 241000219780 Pueraria Species 0.000 claims description 11
- 241000007126 Codonopsis pilosula Species 0.000 claims description 10
- 244000197580 Poria cocos Species 0.000 claims description 10
- 235000008599 Poria cocos Nutrition 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229940010454 licorice Drugs 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 37
- 210000004185 liver Anatomy 0.000 abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000006378 damage Effects 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000000056 organ Anatomy 0.000 abstract description 4
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 2
- 230000002075 anti-alcohol Effects 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 18
- 241001092040 Crataegus Species 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 8
- 244000132619 red sage Species 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 206010036067 polydipsia Diseases 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229920001897 terpolymer Polymers 0.000 description 2
- YKFLAYDHMOASIY-UHFFFAOYSA-N γ-terpinene Chemical compound CC(C)C1=CCC(C)=CC1 YKFLAYDHMOASIY-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940089639 cornsilk Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960003371 protocatechualdehyde Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000001231 zea mays silk Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域Technical Field
本发明涉及保健品技术领域,具体是指一种解酒组合物及其制备方法。The invention relates to the technical field of health care products, in particular to a hangover-relieving composition and a preparation method thereof.
背景技术Background Art
过量饮酒易不仅导致肝损伤及相应的肝病变,而且会引发其他疾病,尤甚者会引起人体生理功能紊乱乃至死亡。过量饮酒导致的酒精性肝损伤已经成为肝病患得的最主要因素之一,于此同时过度酗酒导致患高血压疾病、胃癌等恶性疾、蛋白质等物质发生代谢紊乱时有发生。引起肝脏损伤最常见的毒物是酒精,过量饮酒导致的肝脏损伤已经成为世界性的医学难题。因此,如何醒酒、解酒及减少饮酒对人体胃肠、肝脏等脏器的伤害的需求已迫在眉睫,开发有效的解酒药物具有重要的意义和广阔的市场前景。Excessive drinking can not only cause liver damage and corresponding liver lesions, but also trigger other diseases, and in severe cases, can cause physiological dysfunction and even death. Alcoholic liver damage caused by excessive drinking has become one of the main factors for liver disease. At the same time, excessive drinking often leads to hypertension, gastric cancer and other malignant diseases, and metabolic disorders of substances such as proteins. The most common poison that causes liver damage is alcohol, and liver damage caused by excessive drinking has become a global medical problem. Therefore, the need for how to sober up, relieve alcohol and reduce the damage to the gastrointestinal tract, liver and other organs of the human body caused by drinking is imminent, and the development of effective alcohol-relieving drugs is of great significance and has broad market prospects.
近年来,已有不少解酒的医药保健食品、饮料和药物的报导和产品的上市,如公开号CN 1058907A专利申请采用枳棋子、五味子、葛根配制的“解酒保肝口服液”;公开号CN1238036C专利申请以葛根、枳棋子、陈皮、山碴、玉米须、茯苓配制的“一种纯天然解酒护肝冲剂”。In recent years, there have been many reports and products of medical health foods, beverages and drugs for sobering up, such as patent application No. CN 1058907A for "sobering up and protecting liver oral liquid" prepared with bitter orange seeds, schisandra chinensis and kudzu root; patent application No. CN1238036C for "a pure natural sobering up and protecting liver granule" prepared with kudzu root, bitter orange seeds, tangerine peel, mountain slag, corn silk and poria.
但不同配方的解酒制品的效果是有很大差别的。而且,目前市场上虽有各式解酒醒酒之产品,但功效甚微,效果也欠佳。但多数产品存在适应症较多,治疗范围广,疗效不明确,针对性不强等缺点。而且许多产品只对预防醉酒有效,醉酒后服用则效果不佳;或只注重保肝护肝,对饮酒后较高的血醇浓度无迅速而明显的改善作用。However, the effects of hangover products with different formulas vary greatly. Moreover, although there are various hangover products on the market, they are of little efficacy and poor results. However, most products have disadvantages such as many indications, a wide range of treatments, unclear efficacy, and weak targeting. Moreover, many products are only effective in preventing drunkenness, but not effective after being drunk; or they only focus on protecting the liver, but have no rapid and obvious improvement effect on the high blood alcohol concentration after drinking.
而且目前的解酒药普遍采用分解酒精起到解酒的作用,解酒效果缓慢,只能缓解人体内酒精浓度过高而导致人体不适的症状,但是对酒精引起的肝肾损伤没有保健效果。酒精在肝脏代谢后,会产生有害代谢产物如乙醛,如不加速乙醛的代谢、排泄,会导致更严重的肾脏损伤。同时为了提高解酒效果,现有的解酒药常常添加化学添加剂来提高解酒药的解酒效果,化学添加剂一般经肝脏代谢,经肾脏排泄,长期食用大量添加化学添加剂的食品,在没有经过长期的药理、毒理、临床试验,中药西药合用,容易带来安全隐患。And the current hangover medicine generally uses the decomposition of alcohol to play the role of hangover, and the hangover effect is slow, and can only alleviate the symptoms of human discomfort caused by the high alcohol concentration in the human body, but has no health care effect on the liver and kidney damage caused by alcohol. After alcohol is metabolized in the liver, harmful metabolites such as acetaldehyde will be produced. If the metabolism and excretion of acetaldehyde are not accelerated, more serious kidney damage will be caused. In order to improve the hangover effect, existing hangover medicines are often added with chemical additives to improve the hangover effect of hangover medicines. Chemical additives are generally metabolized by the liver and excreted by the kidneys. Long-term consumption of food with a large amount of chemical additives is not through long-term pharmacology, toxicology, clinical trials, and the combination of Chinese and Western medicines, which easily brings potential safety hazards.
因此,提出一种解酒组合物及其制备方法,以解决目前存在的不足。Therefore, a hangover-relieving composition and a preparation method thereof are proposed to solve the current deficiencies.
发明内容Summary of the invention
本发明要解决的技术问题是克服上述技术的缺陷,提供一种解酒组合物及其制备方法。The technical problem to be solved by the present invention is to overcome the defects of the above-mentioned technology and provide a hangover-relieving composition and a preparation method thereof.
为解决上述技术问题,本发明提供的技术方案为一种解酒组合物及其制备方法,由以下重量配比的原料制成:枳椇子10~40份,葛根10~40份,党参15~35份,炒白术15~35份,茯苓15~45份,生甘草8~35份,陈皮10~30份,山楂10~30份,炒麦芽10~30份,百合15~45份,丹参10~30份。To solve the above technical problems, the technical solution provided by the present invention is a hangover-relieving composition and a preparation method thereof, which is made from the following raw materials in weight ratio: 10-40 parts of Hovenia dulcis, 10-40 parts of Pueraria root, 15-35 parts of Codonopsis pilosula, 15-35 parts of stir-fried Atractylodes macrocephala, 15-45 parts of Poria cocos, 8-35 parts of raw licorice, 10-30 parts of dried tangerine peel, 10-30 parts of hawthorn, 10-30 parts of stir-fried malt, 15-45 parts of lily, and 10-30 parts of Salvia miltiorrhiza.
作为改进,由以下重量配比的原料制成:枳椇子25份,葛根25份,党参27份,炒白术27份,茯苓30份,生甘草21份,陈皮20份,山楂20份,炒麦芽20份,百合30份,丹参20份。As an improvement, it is made from the following raw materials in the following weight ratio: 25 parts of Hovenia dulcis, 25 parts of Pueraria root, 27 parts of Codonopsis pilosula, 27 parts of stir-fried Atractylodes macrocephala, 30 parts of Poria cocos, 21 parts of raw licorice, 20 parts of dried tangerine peel, 20 parts of hawthorn, 20 parts of stir-fried malt, 30 parts of lily, and 20 parts of Salvia miltiorrhiza.
一种解酒组合物的制备方法,包括以下步骤:A method for preparing a hangover-relieving composition comprises the following steps:
S1、原料清洗:将上述原料按照上述质量分数分别称取并清除杂质,用清水进行冲洗干净,然后沥干备用;S1. Raw material cleaning: weigh the above raw materials according to the above mass fractions, remove impurities, rinse with clean water, and then drain for later use;
S2、研磨:将清洗后的上述药物分别进行研磨成细粉,并过100目筛,收集备用;S2, grinding: grinding the washed drugs into fine powder respectively, passing through a 100-mesh sieve, and collecting for later use;
S3、混合:将研磨后的上述药物以此放入搅拌容器内,并搅拌均匀,获得药粉;S3, mixing: putting the ground medicine into a stirring container and stirring evenly to obtain medicine powder;
S4、制备:将混合后得到的药粉与药学上可接受的载体加工成型,得到组合物。S4. Preparation: Processing the mixed powder and a pharmaceutically acceptable carrier into a shape to obtain a composition.
本发明还提供一种解酒组合物,所述组合物包含上述的组合物或者其他药学上可接受的物理形态。The present invention also provides a hangover-relieving composition, which comprises the above composition or other pharmaceutically acceptable physical forms.
作为改进,所述组合物为片剂、口服液、胶囊、颗粒剂或者丸剂。As an improvement, the composition is in the form of tablets, oral liquid, capsules, granules or pills.
作为改进,本发明还提供上述药物在制备能够解酒的组合物的用途。As an improvement, the present invention also provides the use of the above-mentioned drug in preparing a composition capable of sobering up.
所用的各中药材的药理药性如下:The pharmacological properties of the Chinese medicinal materials used are as follows:
枳椇子:味甘,性平,入胃经;有清热、利尿、解酒毒之功效;其中所含的大量葡萄糖、有机酸既能扩充人体血容量,又能解酒毒,具有醒酒安神的作用。现代研究发现枳椇子能够显著降低乙醇在血液中的浓度,促进乙醇的清除。Hovenia dulcis: sweet, neutral in nature, enters the stomach meridian; has the effects of clearing heat, promoting diuresis, and detoxifying alcohol; the large amount of glucose and organic acids contained in it can not only expand the blood volume of the human body, but also detoxify alcohol, and has the effect of sobering up and calming the mind. Modern research has found that Hovenia dulcis can significantly reduce the concentration of ethanol in the blood and promote the removal of ethanol.
同时枳椇子含有皂苷类、黄酮类及生物碱等活性成分,对急性酒精中毒有预防和治疗及保护胃黏膜作用,黄酮类中二氢杨梅素含量较高,其具有抗菌、调节血糖血脂、护肝、抗氧化、抗肿瘤作用;At the same time, Hovenia dulcis contains active ingredients such as saponins, flavonoids and alkaloids, which can prevent and treat acute alcohol poisoning and protect the gastric mucosa. The content of dihydromyricetin in flavonoids is relatively high, which has antibacterial, blood sugar and blood lipid regulation, liver protection, antioxidant and anti-tumor effects.
葛根:味甘、辛,性凉;扩张血管,改善血液循环;降低心肌耗氧量,抑制癌细胞;增加冠脉流量,调整血液微循环;治疗各年龄阶段的突发性耳聋;降低心脑血管疾病危险,心血管的预防与治疗、血糖血脂的调节、循环系统健康、更年期症状调节;Pueraria root: sweet, spicy, cool in nature; dilates blood vessels, improves blood circulation; reduces myocardial oxygen consumption, inhibits cancer cells; increases coronary flow, regulates blood microcirculation; treats sudden deafness at all ages; reduces the risk of cardiovascular and cerebrovascular diseases, prevents and treats cardiovascular diseases, regulates blood sugar and blood lipids, maintains circulatory health, and regulates menopausal symptoms;
党参:味甘,性平;入脾、肺经;甘补而平,补中益气、和胃调中,不燥不腻,用于治疗脾肺气虚,改善食少倦怠,咳嗽虚喘、面色萎黄、四肢乏力的状况。Codonopsis: sweet in taste, neutral in nature; enters the spleen and lung meridians; sweet and tonic but neutral, tonifies the middle and replenishes Qi, harmonizes the stomach and regulates the middle, is neither dry nor greasy, and is used to treat spleen and lung Qi deficiency, improve conditions such as loss of appetite, fatigue, cough, weak asthma, sallow complexion, and weakness in the limbs.
其中黄酮类、生物碱类、糖类、皂苷类、甾体类、氨基酸类和其他类等为主要的活性成分,对胃肠具有一定的调节作用,做到了和胃护肝的功效,同时还具有抗炎症的功能。Among them, flavonoids, alkaloids, sugars, saponins, steroids, amino acids and others are the main active ingredients, which have a certain regulatory effect on the gastrointestinal tract, achieve the effect of soothing the stomach and protecting the liver, and also have anti-inflammatory function.
炒白术:炒白术为白术的炮制品,白术为菊科植物白术的干燥根茎。炒白术甘温补中,味苦燥湿,主归脾胃经。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。具有健脾益气,燥湿利水,止汗、增强细胞免疫等作用,同时具有利尿、保肝、抗肿瘤、利胆、降血糖、抑菌、镇咳、镇静等功效;Stir-fried Atractylodes macrocephala: Stir-fried Atractylodes macrocephala is a processed product of Atractylodes macrocephala, which is the dried rhizome of Atractylodes macrocephala of the Asteraceae family. Stir-fried Atractylodes macrocephala is sweet, warm and nourishing, bitter and dehumidifying, and mainly enters the spleen and stomach meridians. It is used for spleen deficiency, poor appetite, abdominal distension and diarrhea, phlegm and fluid, dizziness and palpitations, edema, spontaneous sweating, and fetal movement disorder. It has the effects of strengthening the spleen and replenishing qi, drying dampness and promoting diuresis, stopping sweating, and enhancing cellular immunity. It also has the effects of diuresis, liver protection, anti-tumor, gallbladder, hypoglycemic, antibacterial, antitussive, and sedative.
茯苓:味甘、淡,性平;归心、肺、脾、肾经;具有利水渗湿,健脾,宁心安神的功效;用于小便不利、水肿胀满、痰饮咳逆、呕吐、脾虚食少、泄泻、心悸不安、失眠健忘、遗精白浊;Poria: sweet, light, neutral in nature; enters the heart, lung, spleen, and kidney meridians; has the effects of promoting diuresis and removing dampness, strengthening the spleen, and calming the mind; used for urinary incontinence, edema, phlegm and cough, vomiting, spleen deficiency, poor appetite, diarrhea, palpitations, insomnia, forgetfulness, and leukorrhea;
生甘草:味甘,性平;归心、肺、脾、胃经;具有补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药的功效;用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性;Raw licorice: sweet, neutral in nature; enters the heart, lung, spleen, and stomach meridians; has the effects of tonifying the spleen and replenishing qi, clearing away heat and detoxifying, removing phlegm and relieving cough, relieving urgency and relieving pain, and harmonizing various medicines; used for spleen and stomach weakness, fatigue, palpitations and shortness of breath, cough with sputum, abdominal and limb cramps and pain, carbuncle, sore and ulcer, and relieves drug toxicity and potency;
陈皮:味苦、辛,性温;归肺、脾经;具有理气健脾,燥湿化痰的功效;用于脘腹胀满,食少吐泻,咳嗽痰多;Tangerine peel: bitter, pungent, warm in nature; enters the lung and spleen meridians; has the effects of regulating qi and strengthening the spleen, drying dampness and resolving phlegm; used for abdominal distension, loss of appetite, vomiting and diarrhea, and cough with excessive phlegm;
陈皮陈皮含有挥发油、橙皮甙、维生素B、C等成分,它所含的挥发油对胃肠道有温和刺激作用,可促进消化液的分泌,排除肠管内积气,增加食欲。陈皮也是一味常用中药,具有通气的健脾、燥湿化痰、解腻留香、降逆止呕的功效;Tangerine peel contains volatile oil, hesperidin, vitamin B, C and other ingredients. The volatile oil it contains has a mild stimulating effect on the gastrointestinal tract, which can promote the secretion of digestive juices, eliminate gas accumulation in the intestines, and increase appetite. Tangerine peel is also a commonly used Chinese medicine, which has the effects of ventilating the spleen, drying dampness and resolving phlegm, relieving greasiness and leaving fragrance, and relieving nausea and vomiting.
山楂:味酸甘,性微温、无毒;归经脾、胃、肝、肺经;消食积、化滞瘀;主治饮食积滞,脘腹胀痛,泄泻痢疾,血瘀痛经,闭经,产后腹痛;恶露不尽。Hawthorn: tastes sour and sweet, slightly warm in nature, and non-toxic; it enters the spleen, stomach, liver, and lung meridians; it can eliminate food accumulation and resolve stagnation and blood stasis; it is mainly used to treat food stagnation, abdominal distension and pain, diarrhea and dysentery, blood stasis and dysmenorrhea, amenorrhea, postpartum abdominal pain, and lochia retention.
山楂味酸甘,入脾、胃、肝经;具有健脾消食的功效,山楂临床应用疗效显著,还具有抗肿瘤、抗炎、镇痛、抗菌、提高机体免疫、降血糖和调血脂等药理活性;Hawthorn tastes sour and sweet, and enters the spleen, stomach, and liver meridians; it has the effect of strengthening the spleen and digesting food. Hawthorn has significant clinical efficacy and also has pharmacological activities such as anti-tumor, anti-inflammatory, analgesic, antibacterial, improving immunity, lowering blood sugar, and regulating blood lipids.
炒麦芽:助消化作用:麦芽煎剂对胃酸与胃蛋白酶的分泌似有轻度促进作用;可以促进人体消化液的分泌,可以加快酒精在体内转化;Roasted malt: Digestive effect: Malt decoction seems to have a mild promoting effect on the secretion of gastric acid and pepsin; it can promote the secretion of human digestive juices and accelerate the conversion of alcohol in the body;
百合:味甘,性微寒;归肺、心、胃经。具有清心除烦,宁心安神,能够消除酒精急性中毒引起的神志恍惚、心情抑郁、燥怒无常;Lily: sweet in taste, slightly cold in nature; enters the lung, heart, and stomach meridians. It has the effect of clearing the heart and relieving restlessness, calming the mind and calming the nerves, and can eliminate the confusion, depression, and irritability caused by acute alcohol poisoning;
丹参:味苦、性微寒;归心、肝经;具有活血祛瘀、通经止痛、清心除烦、凉血消痈的功效;用于胸痹心痛、脘腹肋痛、癥瘕积聚、热痹疼痛、心烦不眠、月经不调、痛经经闭、疮疡肿痛;含有醌类成分、原儿茶醛、原儿茶酸、乳酸、维生素E等成分,具有活血祛瘀、通经止痛、清心除烦、凉血消痈的功能;Danshen: bitter, slightly cold; enters the heart and liver meridians; has the effects of promoting blood circulation and removing blood stasis, relieving pain from menstruation, clearing the heart and eliminating vexation, cooling blood and eliminating carbuncle; used for chest pain, abdominal and rib pain, accumulation of masses, heat arthralgia, insomnia, irregular menstruation, dysmenorrhea, amenorrhea, sores and swelling; contains quinones, protocatechuic aldehyde, protocatechuic acid, lactic acid, vitamin E and other ingredients, has the functions of promoting blood circulation and removing blood stasis, relieving pain from menstruation, clearing the heart and eliminating vexation, cooling blood and eliminating carbuncle;
本发明与现有技术相比的优点在于:枳椇子中含有大量的葡萄糖、有机酸,既能扩充人体的血容量,又能解酒毒,并且含有大量葡萄糖、有机盐、脂类物质,具有促进尿液排泄,加速肠道蠕动等作用;葛根提取物主要含碳水化合物,植物蛋白,多种维生素和矿物质,此外还含有黄酮类物质,经常饮酒,抽烟的人士、酒精代谢中毒者可以摄取葛根提取物,可以预防肝炎,提高肝脏解毒功能,修复肝损细胞。枳椇子和茯苓促进酒精排泄;葛根强肝脏排毒;党参可对肝脏起到保护,同时党参、茯苓健脾运湿,促进中焦气机运化,白术扶正补气而且养胃;陈皮挥发油含有柠檬烯、γ-松油烯等成分,具有平喘,化痰,止咳等功效;百合具有益气补中、益肺止咳的作用,且其含有的秋水仙碱具有抗肝纤维化和肝硬化作用,具有良好的护肝作用;山楂中的山楂多酚有助于中和酒精,促进人体酶活性,加速酒精在血液中的代谢过程,从而起到解酒护肝、缓解酒后不适等作用;丹参成分能够促进血液循环,增加血液的供应和氧气的输送到身体各部分,这有助于减轻疲劳和恢复体力,同时富含抗氧化物质,可以帮助清除自由基,减少氧化应激对肝脏和其他器官的损害;甘草具有调和药性的作用,同样的,该组合物采用纯中药且原料均采用纯天然植物制备,对人体无毒副作用,在实现解酒的同时,达到养护肾脏、肝脏等脏器,以及降血脂,降低血清胆固醇和三酰甘油和治疗酒精肝,大大减少酒精对人体的伤害。Compared with the prior art, the advantages of the present invention are as follows: Hovenia dulcis contains a large amount of glucose and organic acid, which can not only expand the blood volume of the human body, but also detoxify alcohol, and contains a large amount of glucose, organic salts, and lipid substances, which have the effects of promoting urine excretion, accelerating intestinal peristalsis, etc.; Pueraria root extract mainly contains carbohydrates, plant protein, multiple vitamins and minerals, and also contains flavonoids. People who often drink and smoke, and those who are poisoned by alcohol metabolism can take Pueraria root extract to prevent hepatitis, improve the liver's detoxification function, and repair damaged liver cells. Hovenia dulcis and Poria cocos promote alcohol excretion; Pueraria root strengthens the liver and detoxifies; Codonopsis pilosula can protect the liver, while Codonopsis pilosula and Poria cocos can strengthen the spleen and transport dampness, promote the movement of qi in the middle burner, while Atractylodes macrocephala can strengthen the body and replenish qi and nourish the stomach; Tangerine peel volatile oil contains limonene, γ-terpinene and other ingredients, which have the effects of relieving asthma, resolving phlegm, and relieving cough; Lily has the effects of invigorating qi and tonifying the middle, invigorating the lungs and relieving cough, and the colchicine it contains has the effect of resisting liver fibrosis and cirrhosis, and has a good liver protection effect; Hawthorn polyphenols in Hawthorn help neutralize alcohol, promote human enzyme activity, and accelerate the metabolism of alcohol in the blood, thereby playing a role in sobering up, protecting the liver, and relieving alcohol The ingredients in salvia miltiorrhiza can promote blood circulation, increase blood supply and oxygen delivery to various parts of the body, which helps to relieve fatigue and restore physical strength. At the same time, it is rich in antioxidants, which can help to remove free radicals and reduce the damage of oxidative stress to the liver and other organs; licorice has the effect of harmonizing the medicinal properties. Similarly, the composition is made of pure Chinese medicine and the raw materials are all made of pure natural plants. It has no toxic side effects on the human body. While achieving the effect of sobering up, it can also maintain organs such as the kidney and liver, as well as lower blood lipids, reduce serum cholesterol and triglycerides, and treat alcoholic liver, greatly reducing the damage of alcohol to the human body.
具体实施方式DETAILED DESCRIPTION
参选以下本发明的优选实施方法的详述以及包括的实施例可更容易地理解本发明的内容。除非另有限定,本文使用的所有技术以及科学术语具有与本发明所属领域普通技术人员通常理解的相同的含义。当存在矛盾时,以本说明书中的定义为准。The content of the present invention can be more easily understood by selecting the following detailed description of the preferred implementation method of the present invention and the embodiments included. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. When there is a conflict, the definition in this specification shall prevail.
如本文所用术语“由…制备”与“包含”同义。本文中所用的术语“包含”、“包括”、“具有”、“含有”或其任何其它变形,意在覆盖非排它性的包括。例如,包含所列要素的组合物、步骤、方法、制品或装置不必仅限于那些要素,而是可以包括未明确列出的其它要素或此种组合物、步骤、方法、制品或装置所固有的要素。As used herein, the term "prepared from" is synonymous with "comprising." As used herein, the terms "comprising," "including," "having," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, process, method, article, or apparatus that comprises the listed elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, process, method, article, or apparatus.
连接词“由…组成”排除任何未指出的要素、步骤或组分。如果用于权利要求中,此短语将使权利要求为封闭式,使其不包含除那些描述的材料以外的材料,但与其相关的常规杂质除外。当短语“由…组成”出现在权利要求主体的子句中而不是紧接在主题之后时,其仅限定在该子句中描述的要素;其它要素并不被排除在作为整体的所述权利要求之外。The conjunction "consisting of excludes any unspecified element, step, or component. If used in a claim, this phrase renders the claim closed-ended so that it does not include materials other than those described, except for conventional impurities associated therewith. When the phrase "consisting of" appears in a clause of the body of a claim rather than immediately following the subject matter, it limits only the elements described in that clause; other elements are not excluded from the claim as a whole.
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1至2”、“1至2和4至5”、“1至3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。When amount, concentration or other value or parameter is expressed as range, preferred range or a series of upper preferred value and lower preferred value limit range, this should be understood as specifically disclosing all ranges formed by any pairing of any range upper limit or preferred value and any range lower limit or preferred value, regardless of whether the range is disclosed separately. For example, when disclosing range "1 to 5", described range should be interpreted as including range "1 to 4", "1 to 3", "1 to 2", "1 to 2 and 4 to 5", "1 to 3 and 5" etc. When numerical range is described in this article, unless otherwise stated, the range is intended to include its end value and all integers and fractions within the range.
单数形式包括复数讨论对象,除非上下文中另外清楚地指明。“任选的”或者“任意一种”是指其后描述的事项或事件可以发生或不发生,而且该描述包括事件发生的情形和事件不发生的情形。Singular forms include plural references unless the context clearly indicates otherwise. "Optional" or "either" means that the subsequently described event or incident may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
说明书和权利要求书中的近似用语用来修饰数量,表示本发明并不限定于该具体数量,还包括与该数量接近的可接受的而不会导致相关基本功能的改变的修正的部分。相应的,用“大约”、“约”等修饰一个数值,意为本发明不限于该精确数值。在某些例子中,近似用语可能对应于测量数值的仪器的精度。在本申请说明书和权利要求书中,范围限定可以组合和/或互换,如果没有另外说明这些范围包括其间所含有的所有子范围。Approximate terms in the specification and claims are used to modify quantities, indicating that the present invention is not limited to the specific quantity, but also includes acceptable and modified parts close to the quantity without causing changes in the relevant basic functions. Accordingly, the use of "about", "approximately", etc. to modify a numerical value means that the present invention is not limited to the exact numerical value. In some examples, the approximate terms may correspond to the accuracy of the instrument for measuring the numerical value. In the specification and claims of this application, range limitations can be combined and/or interchanged, and if not otherwise stated, these ranges include all subranges contained therein.
此外,本发明要素或组分前的不定冠词“一种”和“一个”对要素或组分的数量要求(即出现次数)无限制性。因此“一个”或“一种”应被解读为包括一个或至少一个,并且单数形式的要素或组分也包括复数形式,除非所述数量明显旨指单数形式。In addition, the indefinite articles "a" and "an" before the elements or components of the present invention have no restrictions on the quantity requirements (i.e. the number of occurrences) of the elements or components. Therefore, "a" or "an" should be interpreted as including one or at least one, and the elements or components in the singular form also include the plural form, unless the number is obviously intended to be in the singular form.
“聚合物”意指通过聚合相同或不同类型的单体所制备的聚合化合物。通用术语“聚合物”包含术语“均聚物”、“共聚物”、“三元共聚物”与“共聚体”。“共聚体”意指通过聚合至少两种不同单体制备的聚合物。通用术语“共聚体”包括术语“共聚物”(其一般用以指由两种不同单体制备的聚合物)与术语“三元共聚物”(其一般用以指由三种不同单体制备的聚合物)。其亦包含通过聚合更多种单体而制造的聚合物。“共混物”意指两种或两种以上聚合物通过物理的或化学的方法共同混合而形成的聚合物。"Polymer" means a polymeric compound prepared by polymerizing monomers of the same or different types. The general term "polymer" includes the terms "homopolymer", "copolymer", "terpolymer" and "interpolymer". "Interpolymer" means a polymer prepared by polymerizing at least two different monomers. The general term "interpolymer" includes the term "copolymer" (which is generally used to refer to a polymer prepared from two different monomers) and the term "terpolymer" (which is generally used to refer to a polymer prepared from three different monomers). It also includes polymers made by polymerizing more monomers. "Blend" means a polymer formed by mixing two or more polymers together by physical or chemical methods.
此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明中。文中所述的较佳实施方法与材料仅作示范之用,但不能限制本申请的内容。In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only and cannot limit the content of this application.
下述实施例中的实验方法,如无特殊说明,均为常规方法;下述实施例中所用的试验材料及试验菌株,如无特殊说明,均为从商业渠道购买得到的。The experimental methods in the following examples are conventional methods unless otherwise specified; the experimental materials and test strains used in the following examples are purchased from commercial channels unless otherwise specified.
实施例一Embodiment 1
一种解酒组合物及其制备方法,由以下重量配比的原料制成:枳椇子10份,葛根10份,党参15份,炒白术15~35份,茯苓15份,生甘草8份,陈皮10份,山楂10份,炒麦芽10份,百合15份,丹参10份。A hangover-relief composition and a preparation method thereof are prepared from the following raw materials in weight proportion: 10 parts of Hovenia dulcis, 10 parts of Pueraria root, 15 parts of Codonopsis pilosula, 15-35 parts of stir-fried Atractylodes macrocephala, 15 parts of Poria cocos, 8 parts of raw liquorice, 10 parts of dried tangerine peel, 10 parts of hawthorn, 10 parts of stir-fried malt, 15 parts of lily and 10 parts of Salvia miltiorrhiza.
一种解酒组合物的制备方法,包括以下步骤:A method for preparing a hangover-relieving composition comprises the following steps:
S1、原料清洗:将上述原料按照上述质量分数分别称取并清除杂质,用清水进行冲洗干净,然后沥干备用;S1. Raw material cleaning: weigh the above raw materials according to the above mass fractions, remove impurities, rinse with clean water, and then drain for later use;
S2、研磨:将清洗后的上述药物分别进行研磨成细粉,并过100目筛,收集备用;S2, grinding: grinding the washed drugs into fine powder respectively, passing through a 100-mesh sieve, and collecting for later use;
S3、混合:将研磨后的上述药物以此放入搅拌容器内,并搅拌均匀,获得药粉;S3, mixing: putting the ground medicine into a stirring container and stirring evenly to obtain medicine powder;
S4、制备:将混合后得到的药粉与药学上可接受的载体加工成型,得到组合物。S4. Preparation: Processing the mixed powder and a pharmaceutically acceptable carrier into a shape to obtain a composition.
本发明还提供一种解酒组合物,所述组合物包含上述的组合物或者其他药学上可接受的物理形态。The present invention also provides a hangover-relieving composition, which comprises the above composition or other pharmaceutically acceptable physical forms.
进一步的,所述组合物为片剂、口服液、胶囊、颗粒剂或者丸剂。Furthermore, the composition is in the form of tablets, oral liquid, capsules, granules or pills.
进一步的,本发明还提供上述药物在制备能够解酒的组合物的用途。Furthermore, the present invention also provides the use of the above-mentioned drug in preparing a composition capable of sobering up.
实施例二Embodiment 2
一种解酒组合物及其制备方法,由以下重量配比的原料制成:枳椇子25份,葛根25份,党参27份,炒白术27份,茯苓30份,生甘草21份,陈皮20份,山楂20份,炒麦芽20份,百合30份,丹参20份。A hangover-relief composition and a preparation method thereof are prepared from the following raw materials in weight proportion: 25 parts of Hovenia dulcis, 25 parts of Pueraria root, 27 parts of Codonopsis pilosula, 27 parts of stir-fried Atractylodes macrocephala, 30 parts of Poria cocos, 21 parts of raw liquorice, 20 parts of dried tangerine peel, 20 parts of hawthorn, 20 parts of stir-fried malt, 30 parts of lily and 20 parts of Salvia miltiorrhiza.
一种解酒组合物的制备方法,包括以下步骤:A method for preparing a hangover-relieving composition comprises the following steps:
S1、原料清洗:将上述原料按照上述质量分数分别称取并清除杂质,用清水进行冲洗干净,然后沥干备用;S1. Raw material cleaning: weigh the above raw materials according to the above mass fractions, remove impurities, rinse with clean water, and then drain for later use;
S2、研磨:将清洗后的上述药物分别进行研磨成细粉,并过100目筛,收集备用;S2, grinding: grinding the washed drugs into fine powder respectively, passing through a 100-mesh sieve, and collecting for later use;
S3、混合:将研磨后的上述药物以此放入搅拌容器内,并搅拌均匀,获得药粉;S3, mixing: putting the ground medicine into a stirring container and stirring evenly to obtain medicine powder;
S4、制备:将混合后得到的药粉与药学上可接受的载体加工成型,得到组合物。S4. Preparation: Processing the mixed powder and a pharmaceutically acceptable carrier into a shape to obtain a composition.
本发明还提供一种解酒组合物,所述组合物包含上述的组合物或者其他药学上可接受的物理形态。The present invention also provides a hangover-relieving composition, which comprises the above composition or other pharmaceutically acceptable physical forms.
进一步的,所述组合物为片剂、口服液、胶囊、颗粒剂或者丸剂。Furthermore, the composition is in the form of tablets, oral liquid, capsules, granules or pills.
进一步的,本发明还提供上述药物在制备能够解酒的组合物的用途。Furthermore, the present invention also provides the use of the above-mentioned drug in preparing a composition capable of sobering up.
实施例三Embodiment 3
一种解酒组合物及其制备方法,由以下重量配比的原料制成:枳椇子40份,葛根40份,党参35份,炒白术35份,茯苓45份,生甘草35份,陈皮30份,山楂30份,炒麦芽30份,百合45份,丹参30份。A hangover-relief composition and a preparation method thereof are prepared from the following raw materials in weight proportion: 40 parts of Hovenia dulcis, 40 parts of Pueraria root, 35 parts of Codonopsis pilosula, 35 parts of stir-fried Atractylodes macrocephala, 45 parts of Poria cocos, 35 parts of raw liquorice, 30 parts of dried tangerine peel, 30 parts of hawthorn, 30 parts of stir-fried malt, 45 parts of lily and 30 parts of Salvia miltiorrhiza.
一种解酒组合物的制备方法,包括以下步骤:A method for preparing a hangover-relieving composition comprises the following steps:
S1、原料清洗:将上述原料按照上述质量分数分别称取并清除杂质,用清水进行冲洗干净,然后沥干备用;S1. Raw material cleaning: weigh the above raw materials according to the above mass fractions, remove impurities, rinse with clean water, and then drain for later use;
S2、研磨:将清洗后的上述药物分别进行研磨成细粉,并过100目筛,收集备用;S2, grinding: grinding the washed drugs into fine powder respectively, passing through a 100-mesh sieve, and collecting for later use;
S3、混合:将研磨后的上述药物以此放入搅拌容器内,并搅拌均匀,获得药粉;S3, mixing: putting the ground medicine into a stirring container and stirring evenly to obtain medicine powder;
S4、制备:将混合后得到的药粉与药学上可接受的载体加工成型,得到组合物。S4. Preparation: Processing the mixed powder and a pharmaceutically acceptable carrier into a shape to obtain a composition.
本发明还提供一种解酒组合物,所述组合物包含上述的组合物或者其他药学上可接受的物理形态。The present invention also provides a hangover-relieving composition, which comprises the above composition or other pharmaceutically acceptable physical forms.
进一步的,所述组合物为片剂、口服液、胶囊、颗粒剂或者丸剂。Furthermore, the composition is in the form of tablets, oral liquid, capsules, granules or pills.
进一步的,本发明还提供上述药物在制备能够解酒的组合物的用途。Furthermore, the present invention also provides the use of the above-mentioned drug in preparing a composition capable of sobering up.
对比例一Comparative Example 1
本对比例提供解酒组合物,其与实施例二的区别仅在于所有组分中不包含党参和白术,其余组分、组分含量与实施例二相同。This comparative example provides a hangover-relieving composition, which differs from Example 2 only in that all components do not contain Codonopsis pilosula and Atractylodes macrocephala, and the remaining components and component contents are the same as those in Example 2.
对比例二Comparative Example 2
本对比例提供解酒组合物,其与实施例二的区别仅在于所有组分中不包含茯苓和生甘草,其余组分、组分含量与实施例二相同。This comparative example provides a hangover-relieving composition, which differs from Example 2 only in that all components do not contain Poria cocos and raw liquorice, and the remaining components and component contents are the same as those in Example 2.
对比例三Comparative Example 3
本对比例提供解酒组合物,其与实施例二的区别仅在于所有组分中不包含陈皮和丹参,其余组分、组分含量与实施例二相同。This comparative example provides a hangover-relieving composition, which differs from Example 2 only in that all components do not contain dried tangerine peel and salvia miltiorrhiza, and the remaining components and component contents are the same as those in Example 2.
为了更好地说明本发明的技术效果,进行以下实验。In order to better illustrate the technical effect of the present invention, the following experiment was conducted.
实验例1:该中药组合物对醉酒小鼠解酒时间的影响试验。Experimental Example 1: Test on the effect of the Chinese medicine composition on the sobering time of drunk mice.
1、实验材料1. Experimental Materials
(1)试验样品:实施例二、对比例一~三所制备的样品。(1) Test samples: samples prepared in Example 2 and Comparative Examples 1 to 3.
(2)实验动物:健康ICR小鼠,SPF级,质量22±3g,雌雄各半,小鼠适应性饲养后1周,小鼠随机分配呈6组,分别为空白对照组、模型对照组、实施例二组、对比例一组、对比例二组、对比例三组,每组10只。(2) Experimental animals: healthy ICR mice, SPF grade, weight 22±3 g, half male and half female. After one week of adaptive feeding, the mice were randomly divided into 6 groups, namely blank control group, model control group, Example 2 group, comparative example 1 group, comparative example 2 group, and comparative example 3 group, with 10 mice in each group.
(3)动物分组处理:试验前禁水禁食,试验时给各组小鼠灌喂56°的红星二锅头白酒,剂量为0.2ml/10g,空白对照组不做处理;模型对照组按0.15ml/10g灌胃蒸馏水;实施例二组用组合物为按照实施例二的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例一组用组合物为按照对比例一的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例二组用组合物为按照对比例二的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例三组用组合物为按照对比例三的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液。(3) Animal grouping and treatment: Before the experiment, mice were deprived of water and food. During the experiment, mice in each group were gavaged with 56° Red Star Erguotou liquor at a dose of 0.2 ml/10 g. The blank control group was not treated; the model control group was gavaged with distilled water at a dose of 0.15 ml/10 g; the composition used in Example 2 group was the composition prepared according to the method of Example 2, and the composition solution of 0.2 g/ml was gavaged at a dose of 0.15 ml/10 g; the composition used in Comparative Example 1 group was the composition prepared according to the method of Comparative Example 1, and the composition solution of 0.2 g/ml was gavaged at a dose of 0.15 ml/10 g; the composition used in Comparative Example 2 group was the composition prepared according to the method of Comparative Example 2, and the composition solution of 0.2 g/ml was gavaged at a dose of 0.15 ml/10 g; the composition used in Comparative Example 3 group was the composition prepared according to the method of Comparative Example 3, and the composition solution of 0.2 g/ml was gavaged at a dose of 0.15 ml/10 g.
实施时,给予白酒后即开始计时,观察并记录给药期间小鼠有无死亡、呕吐、乏力等症状,记录小鼠翻正反射消失和恢复时间,计算小鼠醉倒率和醉酒维持时间(柔和地翻转小鼠,使之处于仰卧位,30s内不能翻正判定为醉酒)。During implementation, the timing started after the administration of liquor, and the death, vomiting, fatigue and other symptoms of the mice during the administration period were observed and recorded. The disappearance and recovery time of the righting reflex of the mice were recorded, and the drunkenness rate and drunkenness maintenance time of the mice were calculated (the mice were gently turned over so that they were in a supine position, and those that could not right themselves within 30 seconds were considered drunk).
以翻正反射为指标观察小鼠醒酒情况,具体醉酒情况见表1。The righting reflex was used as an indicator to observe the soberness of mice. The specific drunkenness conditions are shown in Table 1.
从表1中可看出,与空白对照组、模型对照组相比,实施例二组以及各对比例组小鼠在灌喂白酒后,实施例二组与各对比例组都能有效缩短醉酒维持时间,具有明显的解酒作用,其中对比例组效果类似,而实施例二组的效果明显优于其他组别,醒酒时间最短。说明该组合物对实验动物有较好的解酒作用,能有效缩短醉酒维持时间,并且该组合物种的各个中药成分之间应用中医辩证施治原则合理配伍而得,各个药材之间相互作用,协同共效,配方中缺少部分药材是无法实现对小鼠较好的解酒效果,且本发明组合物对小鼠解酒效果也明显优于其他组合物。As can be seen from Table 1, compared with the blank control group and the model control group, after the mice in the Example 2 group and the comparative example groups were gavaged with liquor, the Example 2 group and the comparative example groups could effectively shorten the duration of drunkenness, and had obvious sobering effect, among which the comparative example group had similar effect, while the Example 2 group had significantly better effect than other groups, and the sobering time was the shortest. This indicates that the composition has a good sobering effect on experimental animals, can effectively shorten the duration of drunkenness, and the various Chinese medicinal ingredients in the composition are reasonably matched according to the principle of Chinese medicine dialectical treatment, the various medicinal materials interact with each other, and have synergistic effects, the lack of some medicinal materials in the formula cannot achieve a good sobering effect on mice, and the sobering effect of the composition of the present invention on mice is also significantly better than other compositions.
实验例2:该中药组合物对酒精性肝损伤小鼠的影响试验。Experimental Example 2: Test on the effect of the Chinese medicine composition on mice with alcoholic liver damage.
(1)试验样品:实施例二、对比例一~三所制备的样品。(1) Test samples: samples prepared in Example 2 and Comparative Examples 1 to 3.
(2)实验动物:健康ICR小鼠,SPF级,质量22±3g,雌雄各半,小鼠适应性饲养后1周,小鼠随机分配呈6组,分别为空白对照组、模型对照组、实施例二组、对比例一组、对比例二组、对比例三组,每组10只。(2) Experimental animals: healthy ICR mice, SPF grade, weight 22±3 g, half male and half female. After one week of adaptive feeding, the mice were randomly divided into 6 groups, namely blank control group, model control group, Example 2 group, comparative example 1 group, comparative example 2 group, and comparative example 3 group, with 10 mice in each group.
(3)动物分组处理:试验前晚禁食禁水,实验时,除空白对照组的小鼠每天灌等体积的蒸馏水;模型对照组、实施例二组以及各对比例组灌喂56°的红星二锅头白酒,剂量为0.2ml/10g,然后模型对照组按0.15ml/10g灌胃蒸馏水;实施例二组用组合物为按照实施例二的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例一组用组合物为按照对比例一的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例二组用组合物为按照对比例二的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液;对比例三组用组合物为按照对比例三的方法制备的组合物,按0.15ml/10g灌胃0.2g/ml的组合物溶液,连续给药7天,末次灌胃后禁食不禁水,12h后取各组小鼠血液样本和肝脏组织进行指标检测。(3) Animal grouping and treatment: The mice were fasted and deprived of water the night before the experiment. During the experiment, except for the blank control group, the mice were gavaged with an equal volume of distilled water every day; the model control group, the Example 2 group and each comparative example group were gavaged with 56° Red Star Erguotou liquor at a dose of 0.2 ml/10 g, and then the model control group was gavaged with distilled water at a dose of 0.15 ml/10 g; the Example 2 group was gavaged with a composition prepared according to the method of Example 2 at a dose of 0.2 g/ml; the comparative example group was gavaged with a composition prepared according to the method of Comparative Example 1. The composition prepared by the method of comparative example 2 was administered intragastrically with a 0.2 g/ml solution of the composition at 0.15 ml/10 g; the composition used in comparative example group 2 was prepared by the method of comparative example 2, and was administered intragastrically with a 0.2 g/ml solution of the composition at 0.15 ml/10 g; the composition used in comparative example group 3 was prepared by the method of comparative example 3, and was administered intragastrically with a 0.2 g/ml solution of the composition at 0.15 ml/10 g. The drugs were administered continuously for 7 days, and the mice were fasted but not watered after the last oral gavage. Blood samples and liver tissues of mice in each group were taken for index detection 12 hours later.
各组血清生化指标的检测结果,详见表2。The test results of serum biochemical indexes in each group are shown in Table 2.
从表2中可以看出,模型对照组与空白对照组相比,ALT、ASL活性显著增高,提示有肝细胞损伤。与模型对照组、实施例组以及对各比例组相比,空白对照组中的血清指标ALT和AST的含量均明显低于模型对照组,说明在长时间灌胃高度酒后小鼠肝脏已经造成损伤。As can be seen from Table 2, compared with the blank control group, the ALT and ASL activities in the model control group were significantly increased, indicating liver cell damage. Compared with the model control group, the embodiment group and the ratio groups, the serum indexes ALT and AST in the blank control group were significantly lower than those in the model control group, indicating that the liver of mice had been damaged after long-term intragastric administration of high alcohol.
与空白对照组以及模型对照组相比,实施例组以及对各比例组中的ALT和AST的含量均高于空白对照组,但是均低于模型对照组,处于模型对照组与空白对照组之间,并且实施例组以及对各比例组数据参数具有显著性差异,Compared with the blank control group and the model control group, the contents of ALT and AST in the embodiment group and each ratio group were higher than those in the blank control group, but lower than those in the model control group, and were between the model control group and the blank control group. In addition, the data parameters of the embodiment group and each ratio group had significant differences.
由此可见,本发明组合物可以显著降低乙醇引起的小鼠血清肝组织中AST、ALT的含量,对饮酒导致的肝损伤具有明显的抑制作用,对酒后肝脏损伤具有良好的保护作用且能够减少肝脏损伤,同时,根据实施例二组与各对比例组的检测数据可知,当减少本发明所述组合物配方中任一组分药材时,则所得该组合物护肝效果显著降低,进一步反面验证该组合物各原料组分之间的协同增强效果。It can be seen that the composition of the present invention can significantly reduce the content of AST and ALT in the serum liver tissue of mice caused by ethanol, has a significant inhibitory effect on liver damage caused by drinking, has a good protective effect on liver damage after drinking and can reduce liver damage. At the same time, according to the detection data of the second embodiment group and each comparative example group, when any component medicinal material in the formula of the composition of the present invention is reduced, the liver protection effect of the obtained composition is significantly reduced, which further verifies the synergistic enhancement effect between the raw material components of the composition.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
以上对本发明及其实施方式进行了描述,这种描述没有限制性,所示的也只是本发明的实施方式之一,实际的结构并不局限于此。总而言之如果本领域的普通技术人员受其启示,在不脱离本发明创造宗旨的情况下,不经创造性的设计出与该技术方案相似的结构方式及实施例,均应属于本发明的保护范围。The present invention and its implementation methods are described above, but such description is not restrictive, and what is shown is only one of the implementation methods of the present invention, and the actual structure is not limited thereto. In short, if ordinary technicians in the field are inspired by it, without departing from the purpose of the invention, they can design a structure and embodiment similar to the technical solution without creativity, which should belong to the protection scope of the present invention.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410941442.XA CN118845957A (en) | 2024-07-15 | 2024-07-15 | A hangover-relieving composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410941442.XA CN118845957A (en) | 2024-07-15 | 2024-07-15 | A hangover-relieving composition and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118845957A true CN118845957A (en) | 2024-10-29 |
Family
ID=93174909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410941442.XA Pending CN118845957A (en) | 2024-07-15 | 2024-07-15 | A hangover-relieving composition and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118845957A (en) |
-
2024
- 2024-07-15 CN CN202410941442.XA patent/CN118845957A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
CN103007145B (en) | Traditional Chinese medicine composition for treating children rotavirus enteritis and preparation method of composition | |
CN110140922A (en) | A kind of ripe honey of low temperature wine | |
CN116138455A (en) | Panax notoginseng polysaccharide extract and its application in the preparation of anti-fatigue products | |
TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
CN114887031A (en) | Anti-alcohol composition and preparation method and application thereof | |
CN118845957A (en) | A hangover-relieving composition and preparation method thereof | |
CN113368225A (en) | Compound prescription for treating diabetes and three highs | |
KR101093006B1 (en) | Method for producing functional health food containing bezoar bovis used microbes and the functional health food produced by the same | |
CN106668409A (en) | Hui traditional Chinese medicine hedyotis diffusa willd anti-esophageal cancer oral liquid and preparation method thereof | |
CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
CN107669910B (en) | Pharmaceutical composition for treating atherosclerosis | |
CN105079703A (en) | Medicine composition for treating infant spleen deficiency type diarrhea and preparation method thereof | |
CN111658720A (en) | Traditional Chinese medicine composition for health preservation, health preserving pill and preparation method | |
CN114668830B (en) | Anti-alcohol and liver-protecting composition and preparation method thereof | |
KR102439636B1 (en) | Composition for alleviating muscle tics and depression and manufacturing method thereof | |
CN115607629B (en) | A traditional Chinese medicine composition capable of protecting liver and relieving alcoholism and preparation method thereof | |
CN110420297A (en) | A kind of Chinese materia medica preparation for anti-trioxypurine | |
CN116832136B (en) | Spleen-strengthening and stomach-harmonizing strawberry tea and preparation method thereof | |
JPH10127256A (en) | Preservative tea for diabetes and its production | |
CN1265821C (en) | Medicine for treating liver cancer and its preparation method | |
CN103861017B (en) | Be used for the treatment of Chinese medicine composition of tuberculous pleural effusion and preparation method thereof | |
CN105664048A (en) | Pharmaceutical composition inhibiting gastric cancer cell proliferation and application thereof | |
CN106668494A (en) | Hui nationality traditional Chinese medicine astragalus membranaceus root stomach cancer-dispersing granules and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |